注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 6月1日，智享生物(苏州)股份有限公司(下称“智享生物”)向港交所主板递交上市申请，东兴证券为独家保荐人。 智享生物成立于2018年4月，是一家中国领先的以生产为驱动的全生命周期合同开发及生产组织(CDMO)，致力于生物制剂。根据弗若斯特沙利文的资料，按2025年商业化产品数量计，智享生物在中国生物制剂CDMO公司中排名第二。而按2025年收入计，智享生物在中国的治疗性抗体药物领域的生物制剂CDMO中排名第三。 智享生物主要提供生物制剂开发及生产的CDMO解决方案，即(i)工艺开发、(ii)分析方法开发及验证、(iii)药品生产质量管理规范(GMP)生产、(iv)质量管理；及(v)监管事务及化学、制造及控制(CMC)支持。 截至最后实际可行日期，智享生物为200多家客户提供CDMO服务，涵盖超过400个项目，涉及200多款药物及候选药物，其中包括3款已获批药物及20多个处于后期开发阶段的项目。 智享生物搭建了六大专有技术平台，覆盖生物

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 近日，苏州血霁生物科技有限公司（以下简称“血霁生物”）正式官宣完成B轮融资二关募集，本轮二关斩获过亿元新增投资，叠加此前B1轮首关融资，公司B轮整体增资规模接近3亿元人民币。 从B1轮首关官宣到二关顺利关闭，血霁生物仅用时四个月，高效完成本轮大额融资落地，充分彰显了资本市场对其核心技术、产品管线与发展前景的高度认可。此次融资将全面赋能公司核心产品临床推进与全新抗衰老管线研发，同时为后续产业化落地与资本化布局筑牢基础。 血霁生物的创始人朱芳芳表示：感谢新老股东对血霁生物的投资。血霁生物将继续坚守初心、稳扎稳打，以市场和临床需求为导向，以旗舰产品为中心，开发围绕血小板世系的多种细胞药物。同时，血霁生物也将迅速完成在资本市场最关键的里程碑，以助力新药最终问世。 据公司披露，完成本次B轮融资后，血霁生物已启动下一阶段资本化规划，将于2026年度内正式开启Pre-IPO轮融资。新一轮融资将重点用于生产基地落地建设、核心产能扩张与产业化配套体系完

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 6月1日，818号令正式实施，同济医院与武汉泓宸创新生物科技有限公司联合申报的“人脊髓GABA能神经前体细胞注射液治疗脊髓损伤的临床研究”通过国家卫健委审核备案，成为全国首个完成备案的神经细胞生物医学新技术项目。 泓宸生物HCXY-001项目成为全国首个备案成功的神经细胞技术项目，是国家权威机构对企业技术路径完整性、临床方案科学性、质量管控严谨性、整体合规体系成熟度的全方位认可，充分彰显了企业在神经细胞治疗领域的技术硬实力与合规软实力。 脊髓损伤是重度中枢神经系统损伤性疾病，现有治疗手段无法修复受损神经组织，患者致残率高。同济医院与泓宸生物依托多能干细胞技术，布局脊髓损伤修复领域，提出神经细胞再生治疗策略。研究表明，移植GABA能神经前体细胞可补充受损神经元、重建神经环路，修复功能、减轻症状。此次备案是项目从实验室走向临床转化的关键节点，为后续收集数据、探索最佳治疗策略奠定基础。 针对这一核心临床痛点，泓宸生物深耕再生医学前沿赛道，依

Funding Comes on the Heels of Novellia Powering Research for the World's Largest Drugmakers, Signing Several Seven-Figure Contracts, and the Launch of Its Patient-Facing Mobile App NEW YORK, June 2, 2026 /PRNewswire/ -- Novellia, the only real-world data company built entirely on information patients choose to contribute to medical research, today announced an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing Novel

Issued on behalf of Conexeu Sciences Inc. A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said. Equity Insider Market Commentary TAMPA, Fla., June 2, 2026 /PRNewswire/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to

One-year, $50,000 grant supports one of the largest efforts to quantify the time burden of cancer clinical trial participation and improve transparency for patients DUARTE, Calif., June 2, 2026 /PRNewswire/ -- AccessHope, LLC, a company expanding access to world‑class cancer expertise, today announced the recipient of the 2026 Conquer Cancer-AccessHope Young Investigator Award (YIA) in Health Services Research and Care Delivery: Hannah Abrams, MD, a hematology-oncology fellow at Fred Hutch Canc

Independent studies found significant improvements in well-being, vitality, sexual health, and key nutritional biomarkers after three months of consistent use LOS ANGELES, June 2, 2026 /PRNewswire/ -- WeNatal, the first prenatal supplement company designed for both women and men, today announced the results of two independent clinical studies evaluating the effects of WeNatal For Her and WeNatal For Him over a three-month period. Continue Reading WeNatal Together Conducted by Citruslabs, an inde

Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehri

EMSCULPT NEO® introduced as part of the team's athlete support program DALLAS, June 2, 2026 /PRNewswire/ -- BTL, a global leader in advanced medical technologies, announced a collaboration with the Dallas Cowboys to support player rehabilitation, recovery, strength, and performance. As part of this initiative, the team has incorporated EMSCULPT NEO® into its athlete recovery and conditioning program, expanding resources to help maintain muscle function and physical readiness throughout the deman

Partnership expands global access to Luminopia's FDA-cleared lead product CAMBRIDGE, Mass., June 2, 2026 /PRNewswire/ -- Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals, with a primary focus on eye care. Amblyopia, or lazy eye, is the leading cause of vision l